14 stories mentioning SHA:600521Updated 6d ago
Every FINWIRES story that references SHA:600521, newest first.
Zhejiang Huahai Pharmaceutical (SHA:600521) received a drug registration certificate from China's medical products administration for telmisartan hydrochlorothiazide tablets.The drug is used to treat essential hypertension, according to a weekend filing with the Shanghai bourse.
Zhejiang Huahai Pharmaceutical (SHA:600521) said four of its drugs were proposed for selection for twelfth batch of China's National Centralized Drug Procurement Program, according to a Monday disclosure on the Shanghai bourse.The drugs are lamotrigine tablets, a treatment for epilepsy, iguratimod tablets, a treatment for active rheumatoid arthritis, hyper tension drug perindopril/amlodipine tablets (III) and mesalazine enteric-coated tablets, a drug for ulcerative colitis and Crohn's disease.
Zhejiang Huahai Pharmaceutical (SHA:600521) has received a drug registration certificate from China's National Medical Products Administration for its Benidipine Hydrochloride Tablets, according to a Shanghai bourse filing Friday.The Class 4 chemical drug is indicated for treating essential hypertension and angina pectoris.Huahai has spent 7.1 million yuan in the research and development of the drug.Shares of the company rose nearly 3% in recent trade.
Zhejiang Huahai Pharmaceutical (SHA:600521) received a drug registration certificate from China's National Medical Products Administration for its ferrous succinate tablets, according to a Shanghai bourse filing on Friday.The drug is indicated for the prevention and treatment of iron-deficiency anemia.The pharmaceutical company's shares dropped 4% during the afternoon trade.
Zhejiang Huahai Pharmaceutical (SHA:600521) will see 54 products and 79 specifications included in China's national essential medicines list in 2026, according to a Saturday filing with the Shenzhen bourse.Among them, 23 products and its 33 specifications are additions to the list, including compound methoxyphenamine capsules and levetiracetam oral solution produced by subsidiary Changxing Pharmaceutical.
Zhejiang Huahai Pharmaceutical's (SHA:600521) U.S. subsidiary Solco Healthcare received tariff refunds of $14.2 million after the Supreme Court ruled tariffs imposed by the Trump administration under the International Emergency Economic Powers Act were invalid, according to a Thursday filing with the Shanghai bourse.The tariff refund represents 36% of the most recent audited net profit and could increase 2026 net profit by 96.9 million yuan.
Zhejiang Huahai Pharmaceutical (SHA:600521) received tariff refunds worth $14.2 million through its subsidiary ScieGen Health USA, according to a Shanghai bourse filing on Thursday.The tariff refunds came after the U.S. Supreme Court ruled that the U.S. government's tariff measures were invalid and the amount should be refunded to importers.The refunds are expected to raise the pharmaceutical company's net profit for the year by 96.9 million yuan.
Zhejiang Huahai Pharmaceutical (SHA:600521) received a drug registration certificate from China's National Medical Products Administration for metaraminol bitartrate injection, according to a Shanghai bourse filing on Friday.The drug is used to treat hypotension.The pharmaceutical company's shares jumped 3% at the close.
Zhejiang Huahai Pharmaceutical (SHA:600521) directors approved the sale of financial assets to raise cash, according to a Saturday filing with the Shanghai bourse.The board has yet to determine the amount of financial assets.
China's National Medical Products Administration accepted the application of Zhejiang Huahai Pharmaceutical's (SHA:600521) unit, Shanghai Huatai Biopharmaceutical, for the marketing of HB0017 injection, according to a Friday disclosure on the Shanghai bourse.The drug is used for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.The pharmaceutical company's shares dropped 4% during the afternoon trade.
China's drug regulator approved Zhejiang Huahai Pharmaceutical's (SHA:600521) iguratimod tablets for rheumatoid arthritis, according to a Tuesday filing with the Shanghai bourse.
Zhejiang Huahai Pharmaceutical (SHA:600521) obtained registration for two drugs from China's medical products administrator.Brexpiprazole tablets are indicated for adult schizophrenia and isavuconazonium sulfate injection for invasive aspergillosis and mucormycosis, according to a weekend filing with the Shanghai bourse.Shares of the drugmaker closed 1% higher Monday.
Zhejiang Huahai Pharmaceutical's (SHA:600521) attributable profit slid 76% to 266.9 million yuan in 2025 from 1.12 billion yuan in 2024, according to a Wednesday filing with the Shanghai bourse.Earnings per share at the drug manufacturer decreased 77% to 0.18 yuan from 0.77 yuan in the previous year.Operating income declined 10% year over year to 8.59 billion yuan from 9.55 billion yuan.Shares increased 2% during morning trading on Wednesday.
Zhejiang Huahai Pharmaceutical (SHA:600521) forecasts its attributable profit will rise 30% to 48% to between 387 million yuan and 440 million yuan in the first quarter from 297.4 million yuan in the year-ago period, according to a Wednesday filing with the Shanghai bourse.The expected rise is attributable to gains from the offloading of a 67% stake in subsidiary Huahai Tianheng (Shanghai) Pharmaceutical Research, the filing said.Shares rose 2% during morning trading on Wednesday.
